NASDAQ$OVID
Ovid Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
OVID Q2 2024 — $196.0M revenue
Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of oper. Ovid Therapeutics Inc reported Q2 2024 results. Net income of $281.0M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $196.0M.
- Net income: $281.0M.
- Operating income: $21K.
Headline financials
Revenue & EPS history
Ovid Therapeutics · Revenue · Quarterly
$169K
Revenue by segment
Ovid Therapeutics · $5.7M total across 1 segment · Q4 2020
- License and other revenue$5.7M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-0.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+3.6%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+19.5%
Q2 2024
Best reaction
-26.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.9% | -5.7% | — | |
| Q4 2025 | +14.4% | +26.9% | +44.8% | |
| Q3 2025 | -2.2% | -3.7% | +21.5% | |
| Q1 2025 | -0.7% | -6.2% | -8.2% | |
| Q4 2024 | +0.1% | -11.4% | -48.0% | |
| Q2 2024 | +19.5% | +33.7% | +31.4% | |
| Q1 2024 | +9.9% | +4.3% | +6.0% | |
| Q4 2023 | -7.3% | -11.0% | +2.5% | |
| Q3 2023 | -7.9% | -4.8% | -9.5% | |
| Q2 2023 | -1.8% | -0.6% | +6.6% | |
| Q1 2023 | -5.2% | -2.5% | +0.1% | |
| Q4 2022 | +4.0% | +13.0% | +46.0% | |
| Q3 2022 | +2.1% | +11.1% | +26.4% | |
| Q2 2022 | +0.5% | +2.3% | -1.4% | |
| Q1 2022 | -12.1% | -22.3% | -30.5% | |
| Q4 2021 | -3.4% | +0.3% | +0.3% | |
| Q3 2021 | -2.8% | +0.8% | -9.7% | |
| Q2 2021 | -9.4% | -13.1% | -14.4% | |
| Q1 2021 | +2.3% | +6.9% | +28.4% | |
| Q4 2020 | +4.4% | +9.0% | -6.1% | |
| Q3 2020 | +18.9% | +19.1% | -49.6% | |
| Q2 2020 | -2.4% | +4.3% | -20.4% | |
| Q1 2020 | -0.3% | +10.6% | +43.7% | |
| Q4 2019 | -26.9% | -31.5% | -7.8% | |
| Q3 2019 | -1.5% | -6.5% | +54.2% | |
| Q2 2019 | -2.1% | -5.2% | +11.9% | |
| Q1 2019 | -14.0% | -20.1% | -24.8% | |
| Q4 2018 | -2.0% | +1.0% | -6.1% | |
| Q3 2018 | -8.0% | -7.9% | -39.1% | |
| Q2 2018 | +2.3% | +8.8% | -0.2% | |
| Q1 2018 | +4.8% | -1.9% | -9.5% | |
| Q4 2017 | -13.1% | -11.4% | +35.7% | |
| Q3 2017 | +15.2% | +20.4% | +49.7% | |
| Q2 2017 | -1.6% | +2.8% | +28.0% | |
| Q1 2017 | +5.3% | +0.4% | -29.7% | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro